

CITATION REPORT

List of articles citing

Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States

DOI: 10.1080/13696998.2020.1761821

Journal of Medical Economics, 2020, 23, 885-893.

Source: <https://exaly.com/paper-pdf/77475597/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1323-1329	2.5	0
5	The impact of anti-monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Neuroimmunology</i> ,	0.4	0
4	Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.		
3	Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.		0
2	Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis. 2023 , 10, 579-588		0
1	Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. 2023 , 26, 494-502		0